Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder
Authors:
- 22 August 2021
- journal article
- letter
- Published by Springer Nature in Annals of Hematology
- Vol. 100 (11) , 2849-2850
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Mycophenolate Mofetil-induced Diffuse Large B-cell Lymphoma in Which a Solitary Lung Nodule Remitted SpontaneouslyInternal Medicine, 2021
- Molecular mechanisms and clinical application of Iguratimod: A reviewBiomedicine & Pharmacotherapy, 2020
- Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disordersJournal of Clinical and Experimental Hematopathology, 2019
- Methotrexate-associated Intravascular Large B-cell Lymphoma in a Patient with Rheumatoid Arthritis: A Very Rare CaseInternal Medicine, 2018
- Imbalance in circulatory iNKT, Th17 and T regulatory cell frequencies in patients with B‑cell non‑Hodgkin's lymphomaOncology Letters, 2017
- Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexateRheumatology, 2017
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis & Rheumatology, 2015
- Clinical manifestation and prognostic factors of 32 Japanese patients with autoimmune disease-associated diffuse large B-cell lymphomaLeukemia & Lymphoma, 2014